Candesartan ameliorates brain inflammation associated with Alzheimer's disease

No abstract is available for this paper.

• Publication year

  2018

• Venue

  CNS Neuroscience & Therapeutics

• Publication date

  2018-01-24

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1111/cns.12802PMID 29365370PMCID PMC6489976
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Candesartan ameliorates brain inflammation associated with Alzheimer's disease

  2018cited by this paper
• Angiotensin II Receptor Blockers Attenuate Lipopolysaccharide-Induced Memory Impairment by Modulation of NF-κB-Mediated BDNF/CREB Expression and Apoptosis in Spontaneously Hypertensive Rats

  2018cited by this paper
• Brain Renin-Angiotensin System and Microglial Polarization: Implications for Aging and Neurodegeneration

  2017cited by this paper
• Beneficial effects of Angiotensin II receptor blockers in brain disorders

  2017cited by this paper
• Activated microglia trigger inflammasome activation and lysosomal destabilization in human RPE cells.

  2017cited by this paper
• Iso-α-acids, Bitter Components of Beer, Prevent Inflammation and Cognitive Decline Induced in a Mouse Model of Alzheimer's Disease*

  2017cited by this paper
• Intranasal telmisartan ameliorates brain pathology in five familial Alzheimer's disease mice.

  2017cited by this paper
• Inflammation in Alzheimer's disease: Lessons learned from microglia-depletion models.

  2017cited by this paper
• An integrative genome-wide transcriptome reveals that candesartan is neuroprotective and a candidate therapeutic for Alzheimer’s disease

  2016cited by this paper
• Evidence to Consider Angiotensin II Receptor Blockers for the Treatment of Early Alzheimer’s Disease

  2016cited by this paper
• Early and protective microglial activation in Alzheimer's disease: a prospective study using 18F-DPA-714 PET imaging.

  2016cited by this paper
• Mechanisms of Aβ Clearance and Degradation by Glial Cells

  2016cited by this paper
• Microglia in Alzheimer's disease: A multifaceted relationship.

  2016cited by this paper
• Telmisartan Modulates Glial Activation: In Vitro and In Vivo Studies

  2016cited by this paper
• Microglia in Alzheimer's disease: the good, the bad and the ugly.

  2016cited by this paper
• Altered microglia morphology and higher resilience to stress-induced depression-like behavior in CX3CR1-deficient mice.

  2016cited by this paper
• Telmisartan prevention of LPS-induced microglia activation involves M2 microglia polarization via CaMKKβ-dependent AMPK activation.

  2015cited by this paper
• Angiotensin Receptor Blockade Modulates NFκB and STAT3 Signaling and Inhibits Glial Activation and Neuroinflammation Better than Angiotensin-Converting Enzyme Inhibition

  2015cited by this paper
• Activation of the nuclear receptor PPARδ is neuroprotective in a transgenic mouse model of Alzheimer’s disease through inhibition of inflammation

  2015cited by this paper
• Classical Renin-Angiotensin system in kidney physiology.

  2014cited by this paper
• Microglia constitute a barrier that prevents neurotoxic protofibrillar Aβ42 hotspots around plaques

  2014cited by this paper
• Angiotensin II type 1 receptor blocker losartan prevents and rescues cerebrovascular, neuropathological and cognitive deficits in an Alzheimer's disease model.

  2014cited by this paper
• Telmisartan attenuates MPTP induced dopaminergic degeneration and motor dysfunction through regulation of α-synuclein and neurotrophic factors (BDNF and GDNF) expression in C57BL/6J mice.

  2013cited by this paper
• Angiotensin II AT1 Receptor Blockers Ameliorate Inflammatory Stress: A Beneficial Effect for the Treatment of Brain Disorders

  2012cited by this paper
• The brain renin–angiotensin system: a diversity of functions and implications for CNS diseases

  2012cited by this paper
• Involvement of PPAR-γ in the neuroprotective and anti-inflammatory effects of angiotensin type 1 receptor inhibition: effects of the receptor antagonist telmisartan and receptor deletion in a mouse MPTP model of Parkinson's disease

  2012cited by this paper
• Brain penetration of telmisartan, a unique centrally acting angiotensin II type 1 receptor blocker, studied by PET in conscious rhesus macaques.

  2012cited by this paper
• Biochemistry and Pharmacology of the Renin-Angiotensin System

  2012cited by this paper
• PPARγ/RXRα-Induced and CD36-Mediated Microglial Amyloid-β Phagocytosis Results in Cognitive Improvement in Amyloid Precursor Protein/Presenilin 1 Mice

  2012cited by this paper
• Angiotensin II AT1 Receptor Blockade Ameliorates Brain Inflammation

  2011cited by this paper
• Angiotensin type 1 receptor modulates macrophage polarization and renal injury in obesity.

  2011cited by this paper
• Blockade of brain angiotensin II AT1 receptors ameliorates stress, anxiety, brain inflammation and ischemia: Therapeutic implications.

  2011cited by this paper
• Losartan inhibits conventional dendritic cell maturation and Th1 and Th17 polarization responses: Νovel mechanisms of preventive effects on lipopolysaccharide-induced acute lung injury.

  2011cited by this paper
• Telmisartan improves insulin resistance and modulates adipose tissue macrophage polarization in high-fat-fed mice.

  2011cited by this paper
• Brain renin-angiotensin--a new look at an old system.

  2011cited by this paper
• Microglia and inflammation in Alzheimer's disease.

  2010cited by this paper
• Angiotensin II sustains brain inflammation in mice via TGF-beta.

  2010cited by this paper
• Protective Effects of Intranasal Losartan in the APP/PS1 Transgenic Mouse Model of Alzheimer Disease

  2010cited by this paper
• Intranasal drug delivery: how, why and what for?

  2009cited by this paper
• Anti-Inflammatory Effects of Angiotensin Receptor Blockers in the Brain and the Periphery

  2009cited by this paper
• Microglia Mediate the Clearance of Soluble Aβ through Fluid Phase Macropinocytosis

  2009cited by this paper
• Identification of Antihypertensive Drugs Which Inhibit Amyloid-β Protein Oligomerization

  2009cited by this paper
• TH-17 cells in the circle of immunity and autoimmunity

  2007cited by this paper
• Valsartan lowers brain beta-amyloid protein levels and improves spatial learning in a mouse model of Alzheimer disease.

  2007cited by this paper
• Role of toll-like receptor signalling in Abeta uptake and clearance.

  2006cited by this paper
• Inflammation and neurodegenerative diseases.

  2006cited by this paper
• Intraneuronal β-Amyloid Aggregates, Neurodegeneration, and Neuron Loss in Transgenic Mice with Five Familial Alzheimer's Disease Mutations: Potential Factors in Amyloid Plaque Formation

  2006cited by this paper
• LPS receptor (CD14): a receptor for phagocytosis of Alzheimer's amyloid peptide.

  2005cited by this paper
• Microglia and inflammation-mediated neurodegeneration: multiple triggers with a common mechanism.

  2005cited by this paper
• Tumor necrosis factor alpha, interleukin-1 beta, interleukin-6 and major histocompatibility complex molecules in the normal brain and after peripheral immune challenge

  2005cited by this paper
• Microglial Phagocytosis Induced by Fibrillar β-Amyloid and IgGs Are Differentially Regulated by Proinflammatory Cytokines

  2005cited by this paper
• Nasal drug delivery--possibilities, problems and solutions.

  2003cited by this paper
• The brain renin-angiotensin system: location and physiological roles.

  2003cited by this paper
• Proteasome inhibition and aggregation in Parkinson's disease: a comparative study in untransfected and transfected cells

  2003cited by this paper
• Clearing the brain's amyloid cobwebs.

  2001cited by this paper
• Chronic peripheral administration of the angiotensin II AT(1) receptor antagonist candesartan blocks brain AT(1) receptors.

  2000cited by this paper
• Inflammation and Alzheimer's disease.

  2000cited by this paper
• Coinduction of Nitric-oxide Synthase and Arginase I in Cultured Rat Peritoneal Macrophages and Rat Tissues in Vivo by Lipopolysaccharide*

  1997cited by this paper
• Slow Degradation of Aggregates of the Alzheimer’s Disease Amyloid β-Protein by Microglial Cells*

  1997cited by this paper
• Journal of Neuroinflammation Expression Profiles for Macrophage Alternative Activation Genes in Ad and in Mouse Models of Ad

  year unknowncited by this paper

• Hyperbolic multivariate feature learning in higher-order heterogeneous networks for drug-disease prediction

  2025cites this paper
• Repositioning of Angiotensin II Receptor Blockers for Alzheimer’s Disease: An In-Silico Study

  2025cites this paper
• Candesartan, an angiotensin receptor blocker, prevents cognitive impairment in female mice with mammary cancer.

  2025cites this paper
• Repurposing immunomodulatory drugs targeting microglia for amyotrophic lateral sclerosis.

  2025cites this paper
• Astrocytes and Microglia in Alzheimer's Disease: Friends, Foes, or Both?

  2025cites this paper
• Inhibition of astrocytic AT1R ameliorates sleep deprivation induced Aβ deposition and glymphatic dysfunction via the MAPK/Cx43 pathway.

  2025cites this paper
• A hydrogel-based nanoparticles sustained-release system selectively targeting pro-inflammatory microglia for spinal cord injury repair.

  2025cites this paper
• Is The Renin-Angiotensin System A Friend or Foe in Neurological Diseases? Unveiling Its Role and Therapeutic Potential.

  2025cites this paper
• Immunomodulatory Effects of RAAS Inhibitors: Beyond Hypertension and Heart Failure

  2025cites this paper
• Renin-angiotensin system as an emerging target to modulate adult neurogenesis in health and disease

  2025cites this paper
• Cranberry Extract Ameliorates Diabetic Cognitive Impairment in Rats Via LncRNA GAS-5 Downregulation and Pyroptosis Pathway Inhibition

  2025cites this paper
• A review: From old drugs to new solutions: The role of repositioning in alzheimer's disease treatment.

  2025cites this paper
• Repurposing Drugs: A Promising Therapeutic Approach against Alzheimer's Disease.

  2025cites this paper
• Microglial AT1R conditional knockout ameliorates hypoperfusive cognitive impairment by reducing microglial inflammatory responses.

  2024cites this paper
• New insights into repurposing of renin-angiotensin system inhibitors against Alzheimer’s disease

  2024influential citation
• Exploring Candesartan, an angiotensin II receptor antagonist, as a novel inhibitor of NLRP3 inflammasome: alleviating inflammation in Neisseria gonorrhoeae infection

  2024cites this paper
• The Contribution of the Renin-Angiotensin System to Alzheimer's Disease.

  2024cites this paper
• Alzheimer’s Disease, Obesity, and Type 2 Diabetes: Focus on Common Neuroglial Dysfunctions (Critical Review and New Data on Human Brain and Models)

  2024cites this paper
• Telmisartan Reduces LPS-Mediated Inflammation and Induces Autophagy of Microglia

  2024cites this paper
• Leveraging generative AI to prioritize drug repurposing candidates for Alzheimer’s disease with real-world clinical validation

  2024cites this paper
• Pomegranate peel extract protects against the development of diabetic cardiomyopathy in rats by inhibiting pyroptosis and downregulating LncRNA-MALAT1

  2023cites this paper
• New Perspectives for Antihypertensive Sartans as Components of Co-crystals and Co-amorphous Solids with Improved Properties and Multipurpose Activity.

  2023cites this paper
• Improvement effects of cyclic peptides from Annona squamosa on cognitive decline in neuroinflammatory mice

  2023cites this paper
• Effect of safranal or candesartan on 3-nitropropionicacid-induced biochemical, behavioral and histological alterations in a rat model of Huntington’s disease

  2023cites this paper
• Therapeutic Implications of Renin–Angiotensin System Modulators in Alzheimer’s Dementia

  2023influential citation
• Comparative Study of Safety and Efficacy of Angiotensin-Receptor Blockers and Anti Amyloid-ß Monoclonal Antibodies for the Treatment of Alzheimer’s Disease: A Systematic Review

  2023cites this paper
• THE POTENT AND SELECTIVE HISTAMINE H3 RECEPTOR ANTAGONIST E169 ALLEVIATES COGNITIVE DEFICITS AND MITIGATES DISTURBED PI3K/AKT/GSK-3Β SIGNALING PATHWAY IN MK801 -INDUCED AMNESIA IN MICE

  2023cites this paper
• Deciphering mechanisms of action of ACE inhibitors in neurodegeneration using Drosophila models of Alzheimer’s disease

  2023cites this paper
• Role of angiotensin receptor blockers in the context of Alzheimer's disease

  2023cites this paper
• Mechanistic Insights for Drug Repurposing and the Design of Hybrid Drugs for Alzheimer's Disease.

  2022cites this paper
• Neuroinflammation: A Potential Risk for Dementia

  2022cites this paper
• SK-Channel Activation Alters Peripheral Metabolic Pathways in Mice, but Not Lipopolysaccharide-Induced Fever or Inflammation

  2022cites this paper
• Microglia Polarization From M1 to M2 in Neurodegenerative Diseases

  2022cites this paper
• Targeting Brain Renin-Angiotensin System for the prevention and treatment of Alzheimer's disease: past, present and future.

  2022cites this paper
• New Paradigm in Cell Therapy Using Sperm Head to Restore Brain Function and Structure in Animal Model of Alzheimer's Disease: Support for Boosting Constructive Inflammation vs. Anti-Inflammatory Approach

  2022cites this paper
• Repositioning of the Angiotensin II Receptor Antagonist Candesartan as an Anti-Inflammatory Agent With NLRP3 Inflammasome Inhibitory Activity

  2022cites this paper
• The immunomodulatory effects of antihypertensive therapy: A review.

  2022cites this paper
• Angiotensin II receptor type 1 blocker candesartan improves morphine tolerance by reducing morphine-induced inflammatory response and cellular activation of BV2 cells via the PPARγ/AMPK signaling pathway

  2022cites this paper
• Modified levels of renin angiotensin related components in the frontal cortex and hippocampus were associated with neuroinflammation and lower neuroprotective effects of NGF during acute hepatic encephalopathy in mice.

  2022cites this paper
• Migraine Pharmacological Treatment and Cognitive Impairment: Risks and Benefits

  2022cites this paper
• Multipronged diagnostic and therapeutic strategies for Alzheimer's disease

  2022cites this paper
• RENEWAL: REpurposing study to find NEW compounds with Activity for Lewy body dementia—an international Delphi consensus

  2022cites this paper
• Candesartan protects against d-galactose induced - Neurotoxicity and memory deficit via modulation of autophagy and oxidative stress.

  2021cites this paper
• Systemic Candesartan Treatment Modulates Behavior, Synaptic Protein Levels, and Neuroinflammation in Female Mice That Express Human APOE4

  2021cites this paper
• Recent advances in molecular pathways and therapeutic implications targeting neuroinflammation for Alzheimer’s disease

  2021cites this paper
• Hydrophilic polymer driven crystallization self-assembly: an inflammatory multi-drug combination nanosystem against Alzheimer's disease.

  2021cites this paper
• Dementia with Lewy bodies: emerging drug targets and therapeutics

  2021cites this paper
• Manifestation of renin angiotensin system modulation in traumatic brain injury

  2021cites this paper
• Angiotensin (1–7) Expressing Probiotic as a Potential Treatment for Dementia

  2021cites this paper
• Olmesartan Prevents Oligomerized Amyloid β (Aβ)-Induced Cellular Senescence in Neuronal Cells.

  2021cites this paper
• Losartan Improves Memory, Neurogenesis and Cell Motility in Transgenic Alzheimer’s Mice

  2021cites this paper
• Central nervous system diseases related to pathological microglial phagocytosis

  2021cites this paper
• Gut microbiota and neuroinflammation in pathogenesis of hypertension: A potential role for hydrogen sulfide.

  2020cites this paper
• Nicotinamide riboside rescues angiotensin II–induced cerebral small vessel disease in mice

  2020cites this paper
• Legumain Knockout Protects Against Aβ1–42-Induced AD-like Cognitive Deficits and Synaptic Plasticity Dysfunction Via Inhibiting Neuroinflammation Without Cleaving APP

  2020cites this paper
• Losartan Treatment Could Improve the Outcome of TBI Mice

  2020cites this paper
• Repositioning medication for cardiovascular and cerebrovascular disease to delay the onset and prevent progression of Alzheimer’s disease

  2020cites this paper
• Pharmacological approaches to mitigate neuroinflammation in Alzheimer's disease.

  2020cites this paper
• Current Status of Drug Targets and Emerging Therapeutic Strategies in the Management of Alzheimer's Disease

  2020cites this paper
• Repurposing Antihypertensive Drugs for the Management of Alzheimer's Disease.

  2020cites this paper
• Solid State Stability and Kinetics of Degradation for Candesartan—Pure Compound and Pharmaceutical Formulation

  2020cites this paper
• Intranasal Losartan Decreases Perivascular Beta Amyloid, Inflammation, and the Decline of Neurogenesis in Hypertensive Rats

  2019cites this paper
• Alzheimer’s dementia: pathogenesis and impact of cardiovascular risk factors on cognitive decline

  2019cites this paper
• Renin-angiotensin system and Alzheimer's disease pathophysiology: From the potential interactions to therapeutic perspectives.

  2019cites this paper
• Hypertension and Its Impact on Stroke Recovery: From a Vascular to a Parenchymal Overview

  2019cites this paper
• Losartan modulates brain inflammation and improves mood disorders and memory impairment induced by innate immune activation: The role of PPAR-γ activation.

  2019cites this paper
• Neuroprotective Approach of Anti-Cancer Microtubule Stabilizers Against Tauopathy Associated Dementia: Current Status of Clinical and Preclinical Findings

  2019cites this paper
• The Anti-inflammatory Compound Candesartan Cilexetil Improves Neurological Outcomes in a Mouse Model of Neonatal Hypoxia

  2019influential citation
• An Overview of Experimental and Clinical Spinal Cord Findings in Alzheimer’s Disease

  2019cites this paper
• Discovery of 4'-OH-flurbiprofen Mannich base derivatives as potential Alzheimer's disease treatment with multiple inhibitory activities.

  2019cites this paper
• Identification of novel immune‐relevant drug target genes for Alzheimer's Disease by combining ontology inference with network analysis

  2018cites this paper
• Targeting Neuroinflammation as a Therapeutic Strategy for Alzheimer's Disease: Mechanisms, Drug Candidates, and New Opportunities.

  2018cites this paper
• Pleiotropic Benefits of the Angiotensin Receptor Blocker Candesartan in a Mouse Model of Alzheimer Disease

  2018cites this paper
• Targeting Neuroin fl ammation as a Therapeutic Strategy for Alzheimer ’ s Disease : Mechanisms , Drug Candidates , and New Opportunities

  2018cites this paper
• The association of multiple anti-hypertensive medication classes with Alzheimer’s disease incidence across sex, race, and ethnicity

  2018cites this paper
• Candesartan ameliorates brain inflammation associated with Alzheimer's disease

  2018cites this paper